Christopher Davis
Biotech operator.Builder. Strategist.
I do deep technical diligence and AI strategy for biotech — backed by 25 years of operating experience, from bench chemistry at Novartis to building and shipping an ML company. Every finding is sourced, every verdict is mine.
25
Years in biotech
$1.2B
Portfolio in scope
50+
Deals evaluated
How I work
Primary-source diligence, shipped in days
Each report traces every claim to a public filing, a trial registry, or a peer-reviewed paper. The analytical stack integrates 2,300+ biomedical tools across 500+ data sources. Three recent examples:
PD-1 agonism for autoimmune disease
Seismic Therapeutic
A mechanism class with one Phase 2b win, two recent Phase 2 failures, and zero peer-reviewed publications on the lead program.
Monitor, do not commit.
Oral miR-124 enhancer for ulcerative colitis
Abivax (ABVX)
Two Phase 3 trials hit induction with 16.4% pooled placebo-adjusted remission (p<0.0001). A $9.3B market cap now rests on a single Q2 2026 maintenance readout.
AAV9-MECP2 gene therapy for Rett syndrome
Neurogene (NGNE)
A pediatric patient died from HLH two weeks after the 3E15 vg dose in November 2024. The high-dose cohort was discontinued.
Consulting
The same rigor, applied to your organization
Hands-on consulting from someone who has built and shipped AI products in pharma — not just advised on them.
AI Strategy Assessment
Evaluate your organization's AI readiness for regulated environments. Identify high-impact opportunities and build a roadmap that clears GxP hurdles from day one.
GxP AI Validation
Validation frameworks for AI/ML systems in pharma and biotech. USP, CLIA/CAP, and FDA experience across cell therapy, diagnostics, and manufacturing.
Fractional CTO
Technical leadership for AI-native biotech startups. From architecture to team-building — founder-level experience without the full-time commitment.
Expert Network Calls
Deep-domain expertise via Third Bridge, AlphaSights, and GLG. Biotech AI, regulatory strategy, and drug discovery — on demand.
Career
Scientist to founder to strategist — building at every stage of the biotech value chain.
BigBio AI
Founder & Principal2023-presentIndependent biotech diligence and AI strategy. Primary-source-verified signal reports for investors and operators. Expert network consulting via Third Bridge, AlphaSights, and GLG.
Mango Inc
Founder & CEO2017-2023Built an ML biotech from zero. Computational microscopy platform cut sterility testing from 14 days to a single shift (200x). Fortune 100 customers. Johnson & Johnson partnership. Sole inventor, PCT patent filed in 5 jurisdictions. Raised $4.24M. Grew team from zero to ~50. Company still operating on founder technology.
Shire Pharmaceuticals
Director, PSPM2015-2017Product strategy for $1.2B GI/IM franchise (Lialda, Pentasa, Gattex). Corp Dev liaison through $32B Baxalta integration. Mydayis commercial launch. 7,000+ Form 2253 assets/week, 100% first-pass approval.
Metamark Genetics
EIR -> Product Manager2014-2015Precision oncology (ProMark). NCCN guidelines inclusion. Initial CLIA/CAP certification. Built MSL team from zero.
Novartis NIBR
Scientist2009-20146M compounds screened across 5 HTS programs. 60K false positives filtered. 4 compound classes advanced to med chem. Published.
University of Calgary / IBI
Co-Founder2004-2008Autonomous drug discovery platform under a MacArthur Fellow. Delivered 10 months early, 35% under budget.
Mass Medical Angels
Member & Due Diligence2015-present50+ seed-stage deals evaluated over ~10 years. Due diligence and investment recommendations.
Let's talk.
Open to operating roles, advisory engagements, and diligence projects. If you're evaluating talent or evaluating a deal, I'd like to hear from you.